Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) EPS (Weighted Average and Diluted) (2021 - 2025)

Relay Therapeutics (RLAY) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.31 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 26.19% to -$0.31 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.61 through Dec 2025, up 31.78% year-over-year, with the annual reading at -$1.61 for FY2025, 31.78% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.31 at Relay Therapeutics, up from -$0.43 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$0.31 in Q4 2025, with the low at -$0.81 in Q2 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.59, with a median of -$0.62 recorded in 2024.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 36.84% in 2023, then skyrocketed 40.58% in 2025.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.62 in 2021, then rose by 11.29% to -$0.55 in 2022, then fell by 21.82% to -$0.67 in 2023, then skyrocketed by 37.31% to -$0.42 in 2024, then increased by 26.19% to -$0.31 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.31, -$0.43, and -$0.41 for Q4 2025, Q3 2025, and Q2 2025 respectively.